RNA Editing Enzyme Associated With Central Nervous System Disorders

Inventor: Kazuko Nishikura

Tech ID: NK-9480

Description: The ADAR (adenosine deaminase that acts on RNA) enzyme, previously known as DRADA, is involved in the RNA editing of glutamate-gated ion channels and the serotonin-2C receptor. This novel enzyme is implicated in central nervous system disorders characterized by abnormal neuronal transmission and intracellular signaling in mammalian brain such as stroke, schizophrenia, depression, and substance abuse.

Applications and Advantages: Wistar researchers have identified an ADAR protein that may be useful for the development of diagnostics and therapeutics for managing conditions associated with glutamate-gated ion channel defects or serotonin receptor defects. Potential applications of ADAR include:
1) Screening assays for novel central nervous system therapeutic agents
2) Diagnostic assays using anti-ADAR antibodies developed at Wistar
3) Generation of therapeutic agents for stroke, depression, schizophrenia or substance abuse

Key Words: Therapeutic, diagnostic, research tool, screening, neurological disease, psychiatric disease, immunoassay, glutamate, serotonin

Intellectual Property Status: This technology is protected by US patents 5,643,778; 5,677,428; and 5,763,174. International patents are pending.

Licensing Opportunity: This technology is available for licensing for development of diagnostic or therapeutic agents. Additionally, antibodies to ADAR are available for licensing for research use.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last updated: Nov. 99